• 中文版
  • Home
  • About Us
    • Contract Research Organization
    • Contract Development and Manufacturing Organization
    • Accolades
    • Publications
  • Services Overview
  • Discovery Chemistry
    • Synthetic Chemistry
    • Medicinal Chemistry
    • Library Chemistry
    • Peptide Chemistry
    • Fragment Based Screening
    • Computer Aided Drug Design
    • Analytical Services
    • Protein Structure
  • Biology & Pharmacology
    • Oncology
    • Pathology Core Facility
    • Immunology
    • Tumor Immunology
    • Neuroscience
    • Cell Biology
    • In Vitro Biology
    • Metabolic & Cardiovascular Diseases
    • Epigenetics
  • Biologics Discovery
    • Antibody Discovery
    • Protein Science
    • Biologics Analytical Services
    • B Cell Cloning
  • DMPK / Exploratory Toxicology
    • DMPK / Exploratory Toxicology
    • Biomarkers, Preclinical & Clinical Sample Bioanalysis
    • Large molecule PK/BA services
  • Biologics CMC
    • Stable Cell Line Development
    • Process Development
    • Formulation Development
    • Aseptic Filling and Freeze-drying
    • Drug Developability / Manufacturability study
    • Final Container Extractables & Leachables Study
    • Analytical Development and Testing
    • GMP Production
  • Small Molecule CMC
    • Process R&D Services
    • Process Safety
    • Analytical Development
    • Pre-Formulation Development
    • Formulation Development
    • ICH Stability Studies
    • CMC CTD Support
    • Manufacturing
  • Blog
  • Careers
  • News & Events
  • Contact Us
  • Download Center

Call us today! +86 21 5132 0088

contact@chempartner.com
中文版
Shanghai ChemPartner Shanghai ChemPartner Shanghai ChemPartnerShanghai ChemPartner
  • Home
  • About Us
    • About ChemPartner
    • CRO
    • CDMO
    • Accolades
    • Publications
  • Services
    • Discovery Chemistry
      • Synthetic Chemistry
      • Medicinal Chemistry
      • Library Chemistry
      • Peptide Chemistry
      • Fragment Based Screening
      • Computer Aided Drug Design
      • Analytical Services
      • Protein Structure
    • Biology & Pharmacology
      • Oncology
      • Pathology Core Facility
      • Immunology
      • Tumor Immunology
      • Cell Biology
      • In Vitro Biology
      • Neuroscience
      • Metabolic & Cardiovascular Diseases
      • Epigenetics
    • Biologics Discovery
      • Antibody Discovery
      • Protein Science
      • Biologics Analytical Services
      • B Cell Cloning
    • DMPK / Exploratory Toxicology
      • DMPK / Exploratory Toxicology
      • Biomarkers, Preclinical & Clinical Sample Bioanalysis
      • Large molecule PK/BA services
    • Biologics CMC
      • Stable Cell Line Development
      • Process Development
      • Formulation Development
      • Aseptic Filling and Freeze-drying
      • Drug Developability / Manufacturability study
      • Final Container Extractables & Leachables Study
      • Analytical Development and Testing
      • GMP Production
    • Small Molecule CMC
      • Process R&D Services
      • Process Safety
      • Analytical Development
      • Pre-Formulation Development
      • Formulation Development
      • ICH Stability Studies
      • CMC CTD Support
      • Manufacturing
  • Blog
  • Careers
  • News & Events
  • Contact Us
  • Download Center

Berkeley Lights and ChemPartner Collaborate on Accelerating Antibody Discovery

6月 28, 2018 | Press Release |

EMERYVILLE, Calif., June 27, 2018 /PRNewswire/ — Berkeley Lights, Inc. (BLI), a leader in digital cell biology, announced today that it has entered into a collaboration with ChemPartner Co., Ltd. (ChemPartner) focused on accelerating ChemPartner’s monoclonal antibody (mAb) discovery workflow utilizing the Beacon® Optofluidic platform. The goal is to expand ChemPartner’s antibody discovery service offerings.

Through the collaboration the companies will combine BLI’s antibody discovery platform for B cells with ChemPartner’s expertise in assay development. The Beacon platform is capable of automatically screening thousands of plasma B cells or gene-edited cells, which speeds up a traditionally time-consuming, manual process. Cell characterizations are performed through a variety of serial or multiplex fluorescence assays to determine antigen-specific binding to membrane-bound targets on live cells, relative affinity, and functional response with reporter cells. Individual cells with the desired characteristics are selected and exported for genomic profiling or further interrogation. Using this platform, plasma B cells can be characterized in less than eight hours.

“This collaboration between ChemPartner and BLI brings together leading technologies and expertise from both companies to offer innovative scientific solutions to the biopharmaceutical industry. We look forward to this exciting beginning to our collaboration with BLI as we continue with our mission to provide our clients with cutting edge science and technology,” said Wei Tang, President of ChemPartner.

“We are excited to collaborate with ChemPartner, an industry-leading Contract Research Organization (CRO) well known for their antibody discovery and development services, to implement the Beacon platform in their monoclonal antibody discovery workflow,” said Andy Last, Chief Commercial Officer at Berkeley Lights, Inc. “Through this program, we plan to deliver a new level of speed and precision that, we believe, is unattainable with other methods.”

To learn more about the Beacon platform’s Antibody Discovery Workflow visit: https://www.berkeleylights.com/beacon-applications/antibody-discovery/

The source URL:https://www.prnewswire.com/news-releases/berkeley-lights-and-chempartner-collaborate-on-accelerating-antibody-discovery-300672784.html

About ChemPartner

Shanghai ChemPartner is a full-service life science CRO with over 15 years of pharmaceutical research experience. With a team of over 2000 experienced scientists, hundreds of western-trained pharmaceutical industry leaders, and experienced pharmaceutical executive leadership at the helm, ChemPartner is aligned and dedicated to technically and strategically accomplishing the research initiatives of pharma and biotech companies worldwide.

www.chempartner.com

About Berkeley Lights:

‪Berkeley Lights, Inc. (BLI) Berkeley Lights is a digital cell biology company that develops and commercializes platforms for the acceleration of discovery, development, and delivery of cell based products and therapies. At the intersection of biology, technology and information, our platforms automate the manipulation, analysis and selection of individual cells, creating ultimate scalability and deep cell insights. The Beacon platform* is ideally suited for cell line development, antibody discovery (including direct B-cell workflows), gene editing, and antibody engineering workflows. Each workflow provides a 100 fold increase in insights, 10 times faster, at a fraction of the cost.

* For Research Use Only. Not for use in diagnostic procedures.

For more information, visit http://www.berkeleylights.com/.

Tags: Berkeley LightsChemPartner
0
Share

You also might be interested in

San Diego, April 5-9, 2014, ChemPartner attended AACR.

San Diego, April 5-9, 2014, ChemPartner attended AACR.

4月 26, 2016

The Americ[...]

Dr. Ming Liu joins ChemPartner as Vice President and Head of Biology and Pharmacology

6月 12, 2018

Shanghai, [...]

ChemPartner at the 18th Shanghai International Froum on Biotechnology & Pharmaceutical Industry

ChemPartner at the 18th Shanghai International Froum on Biotechnology & Pharmaceutical Industry

6月 22, 2016

The 18th I[...]

Latest News

Shanghai ChemPartner was awarded “TOP 10 CMOs in 2019”

Shanghai ChemPartner was awarded “TOP 10 CMOs in 2019”

07/19/2019

Contract manufacturers play a significant role when it ...

Dr. Teddy Yang appointed to Vice President and Head of Biologics Discovery at Shanghai ChemPartner

03/29/2019

Shanghai, China(Mar 28, 2019) – Shanghai ChemPartner to...

ChemPartner Will Participate in BIO-Europe Spring in Vienna, Austria in March 2019

03/18/2019

Shanghai, China (March X, 2019) – March 25-27, 2019, Ch...

ChemPartner will be at the Boulder Peptide Symposium 2018

ChemPartner will be at the Boulder Peptide Symposium 2018

09/25/2018

ChemPartner, a leader in Peptide Synthesis and Developm...

Shanghai  ChemPartner  Announces Merger Deal Closure with Quantum

Shanghai ChemPartner Announces Merger Deal Closure with Quantum

08/16/2018

SHANGHAI, Aug. 16, 2018 /PRNewswire/ — Shanghai  ...

Berkeley Lights and ChemPartner Collaborate on Accelerating Antibody Discovery

06/28/2018

EMERYVILLE, Calif., June 27, 2018 /PRNewswire/ — Berkel...

Tag Cloud

2017 AACR Agreement Antibody Engineering art Berkeley Lights Best Life Science BIOtech Blend Boston Capital Market Chemistry ChemPartner Congratulates CPhI CPSA Shanghai 2016 CRO DMPK Exploratory Toxicology Labs layout Merger Deal PEGS PEGS CHINA Peptide Pharma Pharmacology product PTF Qidong Quantum Hi-Tech China Biological Research Facility San Diego San Francisco Shanghai Shanghai ChemPartner ShangPharma Sponsor Strategic Corporate Restructuring Tarveda Therapeutic Top 10 CMOs Vice President World ADC

Give us a Message

You can leave us a message by quick contact box and we'll get back to you, asap. Thanks!

Send Message

Logo

ChemPartner is a leading research organization providing high-quality and cost-effective services for the pharmaceutical and biotechnology industry.

Get started today.

Contact Us
  • ChemPartner Co., Ltd.
  • 1F & 3F, Block A, 2829 JinKe Road, Zhangjiang Hi-Tech Park, PuDong New Area, Shanghai China, 201203
  • +86 21 5132 0088
  • contact@chempartner.com

© 2019 — Shanghai ChemPartner Co., Ltd. All Rights Reserved  About Us  Careers  Contact Us  Privacy Policy  Sitemap

  • Home
  • Contact
  • Buy Highend
Prev Next